Dietary Supplement Innovation Act

临床试验

计划入组 20 人 · 首次发布于 2019 年 9 月 13 日

已完成

NCT04877366

Evaluate Effects of Sprinkled Format REDUCOSE in a Carbohydrate-rich, Mixed Meal on Post-prandial Glycemia

计划入组 30 人 · 首次发布于 2021 年 5 月 7 日

已完成

NCT04639726

A Study to Evaluate the Effects of Pre-Meal Whey Protein Microgels Administration on Post-Prandial Glycemic Response.

计划入组 26 人 · 首次发布于 2020 年 11 月 20 日

药物

查看全部 680 →

Small Molecule

Investigational

Carnosine

相关疾病：Triple-Negative Breast Cancer

C₉H₁₄N₄O₃

Small Molecule

Approved

Kava

C₁₄H₁₆O₃

Small Molecule

Investigational

ACT-451840

C₄₇H₅₄N₆O₃

机构

查看全部 324 →

SUPPLEMENT FORMULATORS, INC.

United States

ACT Biotech, Inc.

United States

Innovation Exactis

Canada

资讯

查看全部 9964 →

7天前

Dietary Supplement Innovation Act Targets FDA's Drug Preclusion Clause

9个月前

FDA Reverses Course on NMN, Reinstates Dietary Supplement Status After Legal Challenge

2个月前

临床试验

The Effects of Exogenous Ketones on Glucose Tolerance

Evaluate Effects of Sprinkled Format REDUCOSE in a Carbohydrate-rich, Mixed Meal on Post-prandial Glycemia

A Study to Evaluate the Effects of Pre-Meal Whey Protein Microgels Administration on Post-Prandial Glycemic Response.

药物

Carnosine

Kava

ACT-451840

机构

SUPPLEMENT FORMULATORS, INC.

ACT Biotech, Inc.

Innovation Exactis

资讯

Dietary Supplement Innovation Act Targets FDA's Drug Preclusion Clause

FDA Reverses Course on NMN, Reinstates Dietary Supplement Status After Legal Challenge

Dietary Supplement Regulation: What the 2026 Listing Bill Would—and Would Not—Change